Earnings playbook: Palantir and Advanced Micro Devices usher in the next week of reports

Next week, 121 S&P 500 companies, or about 25% of the index, report earnings, led by Walt Disney and McDonald's, while the current season has been strong with 84% of reporting S&P 500 names beating earnings expectations. Key names such as Palantir, Pfizer, AMD, and Uber are expected to show varying combinations of growth, earnings declines, or solid demand, with several management calls and guidance updates likely to drive stock-specific reactions. The article is primarily a forward-looking earnings calendar and analyst preview, with moderate potential to move individual shares but limited broader market impact.

Analysis

The setup favors dispersion over index-level direction. The most interesting read-through is that AI spend is becoming less about headline growth and more about budget durability: if PLTR prints cleanly, it reinforces that enterprise and defense buyers are still willing to fund strategic software even while other IT categories slow, which is constructive for high-multiple “mission critical” software but potentially negative for adjacent analytics and consulting names competing for the same dollars.

AMD is the cleanest second-order tell for semis: a strong report helps confirm that data-center AI demand is broadening beyond the very top of the supply chain, but the stock reaction risk is asymmetric after the recent run. If guidance is merely good rather than exceptional, the market can quickly pivot to margin-compression fears and valuation fatigue, especially if investors decide the near-term upside is already embedded. That makes the next 1-2 trading sessions more of a positioning event than a fundamental one.

Consumer-facing names look more fragile beneath the surface. UBER and MCD both benefit if lower-income consumers remain resilient, but the pressure points are different: UBER is exposed to fuel and weather noise on a weekly basis, while MCD is more about whether value messaging can offset traffic softness without sacrificing mix. A useful tell is whether management commentary points to elastic demand or just promotional support; the latter is less durable and usually means margin risk shows up with a lag of one to two quarters.

The contrarian angle is that the market may be over-penalizing Disney relative to the operational setup and underpricing the strategic reset risk. If new leadership uses the call to signal sharper capital allocation or a clearer streaming/parks priority stack, the stock could re-rate even on modest numbers. Conversely, Pfizer’s catalyst is less about this quarter and more about whether the new oncology asset changes the medium-term growth narrative; one approval can lift sentiment, but commercial execution will matter far more over the next 6-12 months.

Key Decisions for Investors

• Long PLTR into print with a tight post-earnings stop; best risk/reward is a short-dated call spread into the close, looking for a 5-8% upside gap if guidance confirms AI budget durability.
• Fade AMD strength with a tactical short or put spread after the report if the stock rallies on merely solid numbers; target 3-5% downside on valuation reset risk over 1-3 sessions.
• Pair trade: long MCD / short UBER for 2-6 weeks if management commentary confirms U.S. value resilience; MCD has cleaner pricing power while UBER is more exposed to fuel and weather cost noise.
• Buy DIS on confirmation of strategic clarity, not just earnings; use a staggered entry into the call and add only if management addresses capital allocation directly. Upside is a 10-15% re-rate over 1-2 months if the narrative improves.
• Treat PFE as a medium-term optionality trade rather than a quarterly catalyst; if commercialization terms on the new oncology asset look favorable, accumulate on weakness for a 6-12 month recovery setup.